CMS Proposes New Drug Prior-Authorization Rules for Coverage

People who run into insurance delays for prescription drugs may want to watch a new federal proposal, but it is still only a proposal. On April 10, 2026, the Centers for Medicare & Medicaid Services said it wants to extend electronic prior-authorization requirements to drugs for certain plans and public programs, including Medicare Advantage, Medicaid, CHIP, and Qualified Health Plans sold on the federally facilitated ACA marketplaces. CMS also proposed adding small-group marketplace plans in the federally facilitated SHOP program.

The practical point for patients is simple: nothing changes yet. CMS would still need to finalize the rule, and many of the drug-related compliance dates would not begin until October 1, 2027. Plan rules can also vary by insurer, state, and whether a drug is covered under a medical benefit or a pharmacy benefit.

What CMS announced

CMS said the proposal would extend many of the electronic prior-authorization standards from its earlier non-drug rule to drugs. For drugs covered under a medical benefit, impacted payers would have to build coverage and documentation requirements into their prior-authorization application programming interfaces, or APIs. For some Medicaid, CHIP, and federally facilitated marketplace plans, CMS also proposes electronic prior authorization for drugs covered under a pharmacy benefit using National Council for Prescription Drug Programs standards that can support formulary checks, real-time benefit information, and electronic exchanges of prior-authorization requests and decisions.

The affected payer groups named by CMS include Medicare Advantage organizations, state Medicaid and CHIP fee-for-service programs, Medicaid managed care plans, CHIP managed care entities, and Qualified Health Plan issuers on the federally facilitated exchanges.

What is already true now

This proposal builds on CMS’s 2024 Interoperability and Prior Authorization final rule, which focused on medical items and services rather than drugs. Under that rule, affected payers were required to improve electronic data exchange, give a specific reason for a denial, publicly report certain prior-authorization metrics, and, for most impacted payers other than federally facilitated marketplace issuers, send decisions on medical items and services within 72 hours for urgent requests and seven calendar days for standard requests.

That broader reporting framework is already starting to show up. KFF noted that a 2024 federal regulation required certain insurers to begin posting 2025 prior-authorization metrics for medical items and services by March 31, 2026, but those reports still do not show much service-level detail and do not include prescription-drug prior authorization. CMS now proposes to add annual public reporting of drug prior-authorization metrics as well.

Why readers may notice this

If the proposal is finalized, the biggest changes patients may notice are less fax-and-portal paperwork behind the scenes, faster notice of some drug prior-authorization decisions, clearer denial explanations, and more public information about how often drug requests are approved, denied, appealed, or delayed. CMS also proposes making more detailed prior-authorization information available through patient, provider, and payer-to-payer APIs, including status updates, approval or denial dates, end dates, approved drugs and dosage, and denial reasons when applicable.

The proposal’s timing rules are not the same for every program. CMS says Medicaid and CHIP rules would align with existing program requirements, which in some cases means notice within 24 hours for covered outpatient drugs, while federally facilitated ACA marketplace issuers would generally have to notify the requesting provider within 72 hours for standard drug requests and 24 hours for expedited drug requests. That is one reason patients should not assume every plan will operate exactly the same way even if the rule is finalized.

The policy matters because prior authorization is common and can affect access even when care is eventually approved. KFF reported that nearly 53 million prior-authorization requests were submitted to Medicare Advantage insurers on behalf of enrollees in 2024, and more than 80% of appealed denials were at least partly overturned. Those figures help show why even small workflow changes can matter to patients, caregivers, and clinicians.

What will not change yet

As of April 28, 2026, this is not a final rule. CMS says the proposal is open for public comment, which means the agency can revise parts of it before issuing a final version. That matters because the final deadlines, technical standards, reporting rules, and affected plan responsibilities could all change.

What patients can do now if a medication is delayed or denied

Ask whether the medication is being covered under your medical benefit or your pharmacy benefit, because the rules and workflow may differ by plan and drug.
Ask your clinician’s office or pharmacy whether prior authorization is required and whether the request was sent as standard or expedited.
If coverage is denied, ask for the specific reason. CMS’s current and proposed rules put emphasis on giving providers a concrete denial reason, which can matter for resubmission or appeal.
Keep records of dates, reference numbers, letters, portal messages, and phone calls. If an appeal is available, ask about the deadline right away.
Do not stop or change a prescribed medication on your own because of an insurance delay. Ask the prescribing clinician what to do while the coverage issue is being sorted out.

Bottom line

CMS’s April 10 proposal could eventually make drug prior authorization more electronic, more transparent, and in some cases faster for people in Medicare Advantage, Medicaid, CHIP, and certain ACA marketplace plans. But the proposal is not in force yet, and the real-world effect will depend on what survives in the final rule and how insurers and public programs implement it.

Sources

Editorial note: Weence articles are researched from cited public-health, medical, regulatory, journal, and reputable news sources and may be drafted with AI assistance. They are checked for source support, clarity, and safety guardrails before publication.

This article is for general informational purposes only and is not medical advice. Research findings can be early or incomplete, and health guidance can change. Always talk with a qualified healthcare professional about personal symptoms, diagnosis, medications, vaccines, screenings, or treatment decisions. If you think you may have a medical emergency, call emergency services right away.